During the COVID-19 crisis, managed care professionals are facing unique challenges to deliver patient care. This resource center is designed to aggregate timely information for AMCP members and stakeholders.
AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
July 2020 News & Views includes: Doug Long to Discuss Health Care Trends and Impact of COVID-19 at AMCP Webinar, July 9 at 2pm ET; AMCP Foundation Unveils New Mission Statement, Marks 30 Year Anniversary; David Calabrese, 2020 Avey Award Recipient, Shares Insights on Career and Profession; AMCP Corporate Member Spotlight: Scipher Medicine